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Human papilloma virusBackground: Owing to its physical properties, intensity-modulated proton therapy (IMPT) used for
patients with oropharyngeal carcinoma has the ability to reduce the dose to organs at risk compared
to intensity-modulated radiotherapy (IMRT) while maintaining adequate tumor coverage. Our aim was
to compare the clinical outcomes of these two treatment modalities.
Methods: We performed a 1:2 matching of IMPT to IMRT patients. Our study cohort consisted of IMPT
patients from a prospective quality of life study and consecutive IMRT patients treated at a single insti-
tution during the period 2010–2014. Patients were matched on unilateral/bilateral treatment, disease
site, human papillomavirus status, T and N status, smoking status, and receipt of concomitant chemother-
apy. Survival analyzes were performed using a Cox model and binary toxicity endpoints using a logistic
regression analysis.
Results: Fifty IMPT and 100 IMRT patients were included. The median follow-up time was 32 months.
There were no imbalances in patient/tumor characteristics except for age (mean age 56.8 years for
IMRT patients and 61.1 years for IMPT patients, p-value = 0.010). Statistically significant differences were
not observed in overall survival (hazard ratio (HR) = 0.55; 95% confidence interval (CI): 0.12–2.50, p-
value = 0.44) or in progression-free survival (HR = 1.02; 95% CI: 0.41–2.54; p-value = 0.96). The age-
adjusted odds ratio (OR) for the presence of a gastrostomy (G)-tube during treatment for IMPT vs
IMRT were OR = 0.53; 95% CI: 0.24–1.15; p-value = 0.11 and OR = 0.43; 95% CI: 0.16–1.17; p-
value = 0.10 at 3 months after treatment. When considering the pre-planned composite endpoint of grade
3 weight loss or G-tube presence, the ORs were OR = 0.44; 95% CI: 0.19–1.0; p-value = 0.05 at 3 months
after treatment and OR = 0.23; 95% CI: 0.07–0.73; p-value = 0.01 at 1 year after treatment.
Conclusion: Our results suggest that IMPT is associated with reduced rates of feeding tube dependency
and severe weight loss without jeopardizing outcome. Prospective multicenter randomized trials are
needed to validate such findings.
 2016 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 120 (2016) 48–55
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).The prognosis of oropharyngeal cancer (OPC) has improved in
the past decades, especially in terms of locoregional control and
overall survival, likely due to the increased proportion of humanpapillomavirus (HPV)-related tumors. It is now widely accepted
that HPV infection is a major causal factor for OPC, especially
among non-smoking, non-drinking patients [1–3], and is responsi-
ble for the increase in OPC incidence that is observed worldwide,
and notably in North America and Europe. Patients with HPV-
positive OPC are usually younger, have fewer comorbid conditions,
and more often present with lower T status but advanced N status
P. Blanchard et al. / Radiotherapy and Oncology 120 (2016) 48–55 49[4], and have an improved prognosis compared with patients with
HPV-negative disease [5].
Radiotherapy, with or without chemotherapy, is the treatment
of choice for most patients with early [6,7] and advanced [8–10]
OPC because it allows organ preservation and avoids the morbidity
associated with surgical procedures. Avoiding long-term sequelae
of radiation or chemoradiation is particularly important for
patients with OPC as the combination of younger HPV-positive
patients with improved disease control outcomes means survivors
have the potential to live with the side effects and complications of
treatment for many years. Because it maintains dose levels to the
tumor, this strategy could be of interest in all OPC tumors regard-
less of HPV status.
Proton therapy, because of its intrinsic physical properties, has
the ability to reduce the integral dose delivered to the patient
while maintaining highly conformal target coverage. Dosimetric
studies have shown that intensity-modulated proton therapy
(IMPT) allowed dose reductions for various normal tissue struc-
tures, including the contralateral submandibular and parotid
glands, oral cavity, spinal cord and brainstem, as well as the vol-
ume of normal tissue receiving doses of 10, 30, and 50 Gy [11]
and in a pediatric population [12,13]. We previously reported a
dosimetric comparison of the first 25 oropharyngeal cancer
patients treated with IMPT at our institution and found that mean
doses to the anterior and posterior oral cavity, hard palate, larynx,
mandible and esophagus were significantly lower with IMPT than
with IMRT comparison plans generated for the same patients, as
were doses to several central nervous system structures involved
in the nausea and vomiting response [14].
Although dosimetric analyses can be hypothesis-generating,
analyzing comparative clinical outcomes including safety and effi-
cacy of IMPT relative to photon-based IMRT is critical. Therefore,
the aim of this study was to report the first case-matched analysis
of patients with OPC treated with IMPT or IMRT at a single center
from 2010 through 2014.Material and methods
Patient population and matching strategy
From 2011 to 2014, 50 adult OPC patients receiving spot-
scanning IMPT with curative intent were included in an institu-
tional review board-approved observational study in which clinical
outcomes were prospectively recorded. Participants provided
study-specific informed consent. Although tumor outcomes and
toxicity for this population have been reported, a comparative
analysis could not be performed at that time [15]. For comparative
purposes, IMRT patients were selected from our institutional data-
base which included 512 consecutive patients with OPC treated
with IMRT from 2010 to 2012.
IMRT patients were matched with IMPT patients based on fac-
tors that influence treatment volumes and expected toxicity during
or after radiotherapy. A 2:1 ratio was used to increase statistical
power. These factors were, in order: laterality of treatment (unilat-
eral vs bilateral), disease site (tonsil vs base of tongue), p16/HPV
status (positive vs negative, missing data being considered as any
category), T status (T1–T2 vs T3–T4), N status (N0–N1 vs N2–
N3), receipt of concomitant chemotherapy, and smoking status.
For smoking status, the cut-off chosen was 5 pack-years (PY, (65
vs >5 PY) because of difficulty in matching when using the more
widely used cut-off of 10 PY. Further matching was attempted on
age, but even when a large age matching range was used (case
age ±10 years), the addition of this criterion resulted in the loss
of a significant number of patients. We therefore decided not to
match on age but to investigate the age distribution between the
two groups and to adjust the toxicity analyses using this factor.Treatment
The vast majority of OPC cases managed at our institution are
treated with a radiation therapy-based approach, and these results
have previously been reported [16]. Before therapy was begun, all
patients underwent multidisciplinary evaluation within our insti-
tution and all cases were presented at our head and neck cancer
multidisciplinary tumor board for individualized treatment recom-
mendations regarding the sequence and combination of treatment
modalities. All patient underwent nutritional counseling and
follow-up during and after treatment. Gastrostomy (G-) tube
placement was based on a reactive approach, with the decision
made after discussion among the patient, the treating radiation
oncologist, and the dietician. Reasons for G-tube insertion varied
but often included weight loss, inability to maintain oral nutrition,
and dehydration.
Detailed treatment processes were previously described
[15,17,18] and are briefly summarized below. All patients under-
went non-contrast computed tomography (CT) simulation while
immobilized in the supine position with full-length thermoplastic
mask, bite block with or without an oral stent, and a posterior cus-
tomized head, neck and shoulder mold for IMPT patients. During
our Head and Neck Radiation Oncology Planning and Development
Clinic, all IMRT and IMPT patients were examined by at least two
radiation oncologists and target volumes were peer-reviewed for
quality assurance purposes [19]. Gross tumor plus margins were
prescribed a dose of 66 Gy for small volume disease and 70 Gy
for more advanced disease, and elective regions received 54–
63 Gy. For IMPT patients, a relative biological effectiveness (RBE)
value of 1.1 was used. Carefully selected patients with well-
lateralized tonsil cancers underwent ipsilateral neck irradiation
[20,21].
IMPT planning was performed with an Eclipse proton therapy
treatment planning system (version 8.9, Varian Medical Systems,
Palo Alto, California). Typically 3 beams were used for whole-
field bilateral neck IMPT plans: a left and right anterior oblique
and single posterior beam. Multi-field optimization was used for
bilateral treatments, and single-field optimization was used for
unilateral cases. The robustness of each treatment plan was also
considered to evaluate the sensitivity to uncertainties associated
with variations in patient setup and proton beam range in each
patient [22,23]. Plan-specific quality assurance measurements
were made before treatment delivery [24]. Daily kilovoltage image
guidance was used for all patients. Verification CT scans were
obtained at week 1 and 4 of therapy and adaptive re-planning
was considered if inadequate doses were delivered to the targets
or the organs at risk.
IMRT planning was performed with a Pinnacle planning system
(Philips Medical Systems, Andover, MA). Treatment was delivered
with a static gantry approach. The template for patients treated
to both sides of the neck used 9 beams set equidistant through
360 degrees. Plans for patients treated to only one side of the neck
involved a template using 7 beams equidistant through a 190
degree arc. Beam angles and number were modified during the
optimization process. In general, IMRT was used to treat the pri-
mary tumor and upper neck nodes, whereas the lower neck below
the isocenter was treated with an anterior beam, with a larynx
and/or full midline block. A ‘‘whole-field” IMRT approach was used
for situations in which the patient’s anatomy or primary tumor
location created concerns that tumor might be under-dosed using
the ‘‘split-field” approach. IMRT was delivered with Varian (Varian
Medical Systems, Palo Alto CA) linear accelerators as 6-MV photons
with daily image guidance [18]. No systematic re-planning was
performed for IMRT patients. Appropriate recommendations from
the International Commission on Radiation Units and Measure-
ments were followed [25,26].
Table 1
Patient, tumor and treatment characteristics.
Patient characteristics Entire
cohort, n (%)
IMPT, n
(%)
IMRT, n
(%)
p
Age 660 years 90 (60) 23 (46) 67 (67) 0.01
>60 years 60 (40) 27 (54) 33 (33)
Sex Female 22 (14.7) 8 (16) 14 (14) 0.74
Male 128 (85.3) 42 (84) 86 (86)
Tobacco status 0 Pack-Years 70 (46.7) 25 (50) 45 (45) 0.35
0–10 Pack-
Years
21 (14) 4 (8) 17 (17)
>10 Pack-
Years
59 (39.7) 21 (42) 38 (38)
Charlson
comorbidity
index
0–1 134 (89.3) 45 (90) 89 (89) 0.90
P2 16 (10.7) 5 (10) 11 (11)
Tumor site Tonsil 81 (54) 27 (54) 54 (54) 1.00
Base of
tongue
69 (46) 23 (46) 46 (46)
P16 status Positive 131 (87.3) 44 (88) 87 (87) 0.98
Negative 3 (2) 1 (2) 2 (2)
Unknown 16 (10.7) 5 (10) 11 (11)
T Status T1–T2 120 (80) 40 (80) 80 (80) 1.00
T3–T4 30 (20) 10 (20) 20 (20)
N-Status N0–N1 30 (20) 10 (20) 20 (20) 1.00
N2–N3 120 (80) 40 (80) 80 (80)
Induction
chemotherapy
Yes 64 (42.7) 20 (40) 44 (44) 0.64
No 86 (57.3) 30 (60) 56 (56)
RT laterality Bilateral 120 (80) 40 (80) 80 (80) 1.00
Unilateral 30 (20) 10 (20) 20 (20)
Concurrent
chemotherapy
Yes 96 (64) 32 (64) 64 (64) 1.00
No 54 (36) 18 (36) 36 (36)
Cisplatin 39 (41) 13 (41) 26 (41)
Carboplatin 11 (11) 6 (19) 5 (8)
Cetuximab 42 (44) 11 (34) 31 (48)
Taxane 4 (4) 2 (6) 2 (3)
Neck dissection Not
performed
115 (76.7) 41 (82) 74 (74) 0.50
Pre
radiotherapy
14 (9.3) 3 (6) 11 (11)
Post
radiotherapy
21 (14) 6 (12) 15 (15)
Matched variables were unilateral/bilateral treatment, disease site, HPV status, T
and N status, smoking status and receipt of concomitant chemotherapy. The cut-off
used for matching on smoking status (65 PY) was different from the one presented
in the table because of difficulties in matching using the 10 PY cut-off. For p16
matching, patients with unknown p16 status could be considered either p16 pos-
itive or negative.
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All data were prospectively recorded for the IMPT cohort and
retrospectively collected for the IMRT cohort. The data collected
consisted of baseline patient and tumor characteristics, including
smoking status (PY), comorbid conditions according to the Charl-
son comorbidity index [27], p16 status, tumor outcomes, acute/late
toxicity including emergency room visits, and unplanned hospital-
izations. Patient weight, placement of a G-tube during or after radi-
ation therapy, patient-rated fatigue or dry mouth (both of which
were rated on a 0–3 scale from none to severe) were recorded
prospectively in the radiation oncology medical records at each
visit, making the coding process more reliable and reducing the
rate of missing data. Fewer than 5% of data were missing for all
endpoints except for weight loss and fatigue at 1 year after treat-
ment. Toxicity grades considered were peak grade during radio-
therapy and toxicity that persisted at 3 months and at 1 year
after treatment. Toxicity at 2 years after treatment was recorded
but not analyzed because of missing data resulting from the rela-
tively short follow-up time.
Survival times were calculated from the end of radiotherapy to
the date of the first event of interest. Events were defined as fol-
lows: death from any cause for overall survival (OS), death from
any cause or disease recurrence for progression-free survival
(PFS), and locoregional or distant recurrence for locoregional con-
trol and distant control. Patients were censored at their last
follow-up date.
Statistical analysis
Follow-up was calculated by inverting the censoring indicator
and applying the Kaplan–Meier method [28]. The distribution of
categorical variables between IMPT and IMRT patients were com-
pared with chi-square tests. Survival distributions between IMPT
and IMRT were compared with log-rank tests. Survival curves
and estimates of survival at specific time points were computed
with the Kaplan–Meier method. Multivariate survival analyses
were done with Cox regression and included all variables with
p < 0.30 in univariate analysis, along with the case (IMPT)/control
(IMRT) status. The toxicity endpoints (including the composite
endpoint of G-tube and grade 3 weight loss) and the statistical
analysis plan were predefined before the statistical analysis, in
an effort to inform the endpoint of a future phase III trial. Toxicity
rates are reported as the frequency and percentage of patients with
toxicity information at a specified time point. IMPT and IMRT
patients were further compared by multivariate logistic regression,
which included age dichotomized at 60 years as a covariate. Dura-
tion of G-tube placement was compared between IMPT and IMRT
patients with log-rank tests using the removal of feeding tube as
an event and censoring patients who died with a feeding tube in
place. All p-values reported are 2-sided and a p < 0.05 was consid-
ered statistically significant. Statistical analyses were conducted
using SAS software (Release 9.3; SAS Institute, Cary, NC, USA).
Results
Patient, tumor and treatment characteristics are presented in
Table 1. No imbalances were found between the two groups in
any covariate apart from patient age (p-value = 0.01). Median age
(range) was 61 years (37–84) for IMPT patients and 55.5 years
(34–78) for IMRT patients. Patients had few comorbidities (Charl-
son comorbidity index of 0–1 in 89.3%). Most tumors were locally
advanced (N2–N3 in 80%). Most tumors were HPV-positive, with
only three HPV-negative tumors and 16 patients with unknown
HPV status. Approximately 43% of the patients received induction
chemotherapy and two-thirds received concurrent chemotherapy.
Unilateral radiotherapy was delivered to 20% of the patients.Median follow-up time was 32 months (range 2–55) for the
entire cohort, 29 months (range 8–49) for the IMPT group and
33 months (range 2–55) for the IMRT group. Owing to differences
in the inclusion period, the number of living patients censored
before 2 years of follow-up after treatment was 21 (42%) in the
IMPT group and 13 (13%) in the IMRT group. Twelve patient deaths
were recorded, two in the IMPT group and ten in the IMRT group.
OS rates at 3 years were 94.3% in the IMPT group and 89.3% in the
IMRT group. Results from the Cox regression are reported in
Table 2. In univariate analyses, only advanced T status and the
insertion of a G-tube at the acute phase were associated with
decreased OS, with hazard ratios (HR) of 3.1 (95% confidence inter-
val (CI): 0.98–9.8, p-value = 0.05) and 6.61 (95% CI: 1.8–24.4, p-
value = 0.005), respectively. In multivariate analyses, the insertion
of a G-tube at the acute phase was the only significant factor affect-
ing OS, with a HR of 4.96 (95% CI: 1.1–23.0, p-value = 0.04). The HR
between IMPT and IMRT in multivariate analysis was 0.55 (95% CI:
0.12–2.5, p-value = 0.44).
Twenty-two events (recurrence or death)were observed, 7 in the
IMPT group and 15 in the IMRT group, leading to a 3-year PFS rate of
86.4% in the IMPTgroup and85.8% in the IMRTgroup, corresponding
to a HR of 1.02 (95% CI: 0.41–2.54, p-value = 0.96). The results from
the PFS analysis are presented in Table 3. PFS curves according to
Table 2
Univariate and multivariate analyses for overall survival.
Patient characteristics Univariate Multivariate
HR (95% CI) p HR (95% CI) p
RT type IMRT 1 1
IMPT 0.42 (0.09–1.91) 0.26 0.55 (0.12–2.5) 0.44
Age 660 years 1 –
>60 years 1.6 (0.50–4.89) 0.44 –
Sex Female 1 –
Male 1.71 (0.22–13.2) 0.61 –
Tobacco status 0 PY 1 –
0–10 PY 1.63 (0.3–8.9) 0.57 –
>10 PY 1.73 (0.49–6.1) 0.39 –
Charlson comorbidity index 0–1 1 1
P2 3.2 (0.87–11.9) 0.08 3.39 (0.81–14.1) 0.09
Tumor site Tonsil 1 –
Base of tongue 1.17 (0.38–3.6) 0.79 –
P16 status Positive 1 –
Negative NA –
Unknown 1.61 (0.35–7.4) 0.54 –
T Status T1–T2 1 1
T3–T4 3.1 (0.98–9.8) 0.05 1.36 (0.35–5.4) 0.65
N-Status N0–N1 1 1
N2–N3 2.97 (0.38–23.1) 0.30 1.38 (0.14–13.4) 0.78
Induction chemotherapy No 1 1
Yes 2.66 (0.80–8.8) 0.11 1.96 (0.52–7.4) 0.32
RT laterality Bilateral 1 –
Unilateral NA –
Concurrent chemotherapy No 1 1
Yes 3.02 (0.66–13.8) 0.15 1.16 (0.20–6.8) 0.91
Neck dissection Not performed 1 –
Pre radiotherapy 1.03 (0.13–8.3) 0.98 –
Post radiotherapy 2.06 (0.55–7.8) 0.28 –
Acute G-tube insertion No 1 1
Yes 6.61 (1.8–24.4) 0.005 4.96 (1.1–23.0) 0.04
Weight loss at 3 months after RT <20% 1 –
P20% 0.86 (0.11–6.8) 0.88 –
NA: not assessed. Hazard ratios (HRs) were not estimated for HPV-negative or unilateral RT patients because of the very low numbers of patients/events in these groups.
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variate analyses, advanced age (HR = 2.70; 95% CI: 1.10–6.90; p-
value = 0.04) and the insertion of a G-tube at the acute phase
(HR = 3.09; 95% CI: 1.19–8.00; p-value = 0.02) were associated with
decreased PFS. T statuswas close to significance in the univariate (p-
value = 0.08) but not in the multivariate analysis.
Overall, 15 locoregional relapses, 5 in the IMPT and 10 in the
IMRT group, were observed. Eight distant relapses were observed,
1 in the IMPT group and 7 in the IMRT group. Three-year locore-
gional control rates were 91.0% for IMPT patients and 89.7% for
IMRT patients. Three-year distant control rates were 97.8% for
IMPT patients and 93.5% for IMRT patients. No significant differ-
ences were found between the IMPT and IMRT groups with respect
to locoregional control (HR = 1.03; 95% CI: 0.35–3.02; p-
value = 0.96) and distant control (HR = 0.33; 95% CI: 0.04–2.74; p-
value = 0.30). In the univariate analysis, locoregional control was
significantly decreased by advanced T status (p-value = 0.04) and
acute G-tube insertion (p-value = 0.03). Probably because of the
low rate of events, no significant factor was found in the multivari-
ate analysis for either of these endpoints.
The association between acute G-tube placement and survival
was studied. The PFS curves according to acute G-tube placement
are shown in Supplementary Fig. 1. Patients receiving a G-tube
during radiotherapy had a longer history of tobacco smoking (p-
value = 0.03), a higher Charlson comorbidity index (p-
value = 0.03), more advanced T and N status (p-values = 0.01 and
0.07), more frequent bilateral treatment (p-value < 0.001), use of
induction chemotherapy (p-value = 0.07) and concurrent
chemotherapy (p-value < 0.001), and a longer treatment duration
(by a mean 2 days; 43 vs 41 days, p = 0.0002). Sensitivity analysesfor PFS were done for this group without using acute G-tube place-
ment as a variable and yielded comparable results as the initial
analyses, with no statistically significant difference between the
IMPT and IMRT groups (HR: 0.82; 95% CI:0.32–2.1; p-value = 0.67).
No significant differences were found in acute grade 3 or higher
dermatitis or mucositis between the IMPT and IMRT patients (p-
values = 0.15 and 0.90). Toxicity endpoints between treatment
groups are described in Table 4. The median duration of G-tube
placement was 2.8 months in the IMPT group and 4.8 months in
the IMRT group (p-value = 0.12). The age-adjusted OR for the use
of a G-tube were 0.53 (95% CI: 0.24–1.15; p-value = 0.11) during
treatment and 0.43 (95% CI: 0.16–1.17; p-value = 0.10) at 3 months
after treatment. Grade 3 weight loss at 1 year after treatment may
have been more prevalent in the IMPT group, with an OR of 0.28
(95% CI: 0.08–1.05; p-value = 0.06). When considering the prede-
fined composite index of G-tube use or grade 3 weight loss, the
ORs at 3 months and 1 year after treatment were 0.44 (95% CI:
0.19–1.0, p-value = 0.05) and 0.23 (95% CI: 0.07–0.73, p-
value = 0.01). Patient-reported grade 2 or higher xerostomia at
3 months was less common among the IMPT patients, with an
OR of 0.38 (95% CI: 0.18–0.79, p-value = 0.009). No differences
were found between the two groups in grade 2 or higher patient-
reported fatigue at any time, in the frequency of emergency room
visits, or in unscheduled hospitalizations.
Discussion
This comparative clinical study of patients with OPC treated
with IMPT or IMRT suggests that IMPT may achieve toxicity reduc-
tion while preserving tumor control. Our study showed that IMPT,
Table 3
Univariate and multivariate analyses for progression free survival.
Patient characteristics Univariate Multivariate
HR (95% CI) p HR (95% CI) p
RT type IMRT 1 1
IMPT 1.02 (0.41–2.54) 0.96 1.00 (0.39–2.6) 0.99
Age 660 years 1 1
>60 years 3.08 (1.28–7.41) 0.01 2.7 (1.1–6.9) 0.04
Sex Female 1 –
Male 1.43 (0.33–6.12) 0.63 –
Tobacco status 0 PY 1 –
0–10 PY 0.94 (0.19–4.51) 0.93 –
>10 PY 2.14 (0.85–5.37) 0.10 –
Charlson comorbidity index 0–1 1 1
P2 2.35 (0.79–7.04) 0.13 1.83 (0.6–5.8) 0.31
Tumor site Tonsil 1 –
Base of tongue 1.03 (0.44–2.4) 0.94 –
P16 status Positive 1 –
Negative NA –
Unknown 1.25 (0.37–4.3) 0.72 –
T Status T1–T2 1 1
T3–T4 2.27 (0.91–5.64) 0.08 1.15 (0.40–3.31) 0.80
N-Status N0–N1 1 –
N2–N3 1.11 (0.37–3.3) 0.85 –
Induction chemotherapy No 1 –
Yes 1.38 (0.60–3.2) 0.45 –
RT laterality Bilateral 1 –
Unilateral 0.57 (0.16–1.92) 0.36 –
Concurrent chemotherapy No 1 –
Yes 1.37 (0.55–3.37) 0.50 –
Neck dissection Not performed 1 –
Pre radiotherapy 1.12 (0.25–4.96) 0.88 –
Post radiotherapy 2.18 (0.83–5.8) 0.11 –
Acute G-tube insertion No 1 1
Yes 3.27 (1.39–7.66) 0.006 3.09 (1.19–8.00) 0.02
Weight loss at 3 months after RT <20% 1 –
P20% 0.91(0.21–3.93) 0.90 –
Fig. 1. Progression free survival according to type of ionizing radiation (IMPT vs
IMRT).
52 Proton versus photon therapy for oropharynx cancerwhen compared with IMRT, achieves similar cure rates, by both OS
and disease control measures, after a median follow-up time of
nearly 3 years. With regard to toxicity, IMPT may have resulted
in a reduction of G-tube rates during the acute phase, at 3 months,
and 12 months. When using a pre-planned composite endpoint of
G-tube or grade 3 weight loss, IMPT was associated with signifi-
cantly reduced rates of toxicity at both 3 months and 12 months
after treatment.These clinical results are consistent with a recent case-matched
analysis of patients with nasopharyngeal carcinoma published by
our institution [29] and a recent comparative study in patients
receiving ipsilateral head and neck radiotherapy [30], and the rates
of G-tube placement are within the range of those reported in ran-
domized trials [31]. One unexpected finding in the current study is
that acute G-tube placement was a significant adverse prognostic
factor for OS and PFS. An analysis of G-tube placement demon-
strated strong associations with many adverse features, including
greater intensity of treatment as measured by bilateral radiation
and use of chemotherapy, more advanced disease, and smoking
with have a higher incidence of comorbidities. G-tube placement
was also associated with a small (mean 2 days) but statistically sig-
nificant longer treatment duration, potentially affecting treatment
outcome. Therefore, it is likely that G-tube placement is a proxy for
advanced disease and more intensive treatment rather than a cau-
sal factor for future disease progression. Nevertheless, reducing the
need for feeding tube placement during radiotherapy and at the
chronic phase could be an important goal to reduce toxicity and
improve patient quality of life [32].
The limitations of this study are related to the retrospective
coding of IMRT patients, which is known to underestimate toxicity
relative to prospective coding. However, the main endpoints, G-
tube and weight loss, were limited to the use of objective measures
that were captured at the time of occurrence. Further, patient-
reported levels of fatigue and dry mouth were collected on a regu-
lar basis and in a consistent fashion during the entire period of
accrual. The prospective coding of IMPT patients, who were all
included in quality of life evaluation cohorts, ensures high quality
data. The practice regarding feeding tube placement at our institu-
tion is reactive and involves the patient along with several
Table 4
Toxicity analysis for pre-planned endpoints between IMPT and IMRT at various time points, adjusted for patient age (dichotomized at 60 years).
Endpoint During RT 3-months post RT 1 year post RT
IMPT n
(%)
IMRT n
(%)
OR (95% CI) p IMPT n
(%)
IMRT n
(%)
OR (95% CI) p IMPT n
(%)
IMRT n
(%)
OR (95% CI) p
G-tube presence 12 (24) 38 (38) 0.53
(0.24–1.15)
0.11 6 (12) 23 (23) 0.43
(0.16–1.17)
0.10 1 (2) 7 (7.8) 0.16
(0.02–1.37)
0.09
Weight loss > 20% compared to
baseline
– – – – 4 (8.3) 13
(13.5)
0.64
(0.19–2.11)
0.46 3 (6.7) 17
(19.3)
0.28
(0.08–1.05)
0.06
G-tube OR weight loss > 20% – – – – 9 (18) 34 (34) 0.44
(0.19–1.0)
0.05 4 (8) 22
(24.7)
0.23
(0.07–0.73)
0.01
Patient rated xerostomia grade
2–3
– – – – 21 (42) 60
(61.2)
0.38
(0.18–0.79)
0.009 21 (42) 42
(47.2)
0.63
(0.30–1.33)
0.23
Patient rated fatigue grade 2–3 39 (78) 84
(86.6)
0.49
(0.20–1.23)
0.13 20
(40.8)
34
(36.2)
1.1
(0.53–2.27)
0.80 7 (14.6) 17
(22.1)
0.5
(0.18–1.36)
0.17
Emergency room visit 16 (32) 32 (32) 0.95
(0.45–2.0)
0.89 – – – – – – – –
Unscheduled hospitalization 10 (20) 21 (21) 0.92
(0.39–2.2)
0.84 – – – – – – – –
OR represent the risk of toxicity in IMPT patients compared to IMRT patients. OR was not calculated for G-tube presence at one year post treatment because no patient was
present in the IMPT group, but a p-value was calculated using a chi-2 Fisher exact test.
Abbreviations: CI, confidence interval; ND, not determined; OR, odds ratio; RT, radiotherapy.
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might have been discouraged in IMPT patients, but this would have
likely translated into increased weight loss, which was not
observed. Also, even though the placement of a feeding tube might
be physician-biased, feeding tube dependency in the long run, at
3 months and 1 year, is a strong surrogate for chronic swallowing
dysfunction and/or functional limitations on taste and saliva pro-
duction with negative implications for quality of life [32,34].
Reducing these late side effects is an important goal, especially
given the high survival rates observed in patients with HPV-
positive disease.
The second limitation is the absence ofmatching on age. Because
increasing age is known to be associated with increasing acute and
late toxicity [35,36], and especially feeding tube dependence, toxic-
ity analyseswere all age-adjusted. However, the IMPT patientswere
significantlyolder than their IMRT counterparts,most likely because
approval of IMPT for older patient is easier because they are covered
byMedicare. This age difference should favor IMRTpatients in terms
of toxicity and, notably, late feeding tubes. In our group, age above
60 years was found to be associated only with increased patient-
reported xerostomia level at 3 months and at 1 year after treatment.
Nevertheless, although patients were matched on several factors,
the presence of unmeasured confounding factors or selection bias
cannot be ruled out. This study remains hypothesis-generating
and needs prospective independent validation.
Several outcomes of interest that might differ between treat-
ment groups, either subjective or objective, such as osteora-
dionecrosis, late mucosal or neuromuscular toxicity, or acute
nausea, could not be collected rigorously from the IMRT group or
because of the relatively short follow-up time of this study, and
have not been analyzed. Other important items, such as full
patient-reported outcomes or utility metrics, would be of interest,
and some have been collected from the IMPT group but unfortu-
nately were not available from the IMRT group.
One major unanswered question relates to the selection of
patients for proton therapy. We anticipate, based on predicted tox-
icity, that some subgroup of patients will have improved swallow-
ing and salivary function with IMPT compared with IMRT
[34,37,38]. The present study does not provide insight into this
issue of patient selection, but rather suggests that differences in
toxicity pattern can be detected in a non-selected OPC patient pop-
ulation. The allocation of this scarce and expensive resource based
on expected patient benefit is a reasonable option that will, how-
ever, require prospective validation.Indeed, in the current context of debate about the costs associ-
ated with technology improvements in radiation oncology, and
especially the cost of proton therapy, this report sheds new light
on the potential value of IMPT for treating OPC. Although the deliv-
ery of proton therapy is about two to three times more expensive
than the delivery of IMRT [39,40], reducing treatment toxicity in
the acute, subacute, and chronic phases is a major goal for patients
with OPC that could lead to increased quality of life, improved job
return, and decreased healthcare utilization if costs are considered
over the entire disease cycle [39]. Value is defined as the outcomes
that matter most to the patients divided by the cost of care [41].
Evaluating value therefore requires an investigation of which out-
comes matter to patients. Late dysphagia has been found to be a
major correlate of decreased quality of life [42], and before and
after treatment patients prioritize swallowing abilities among
other functional outcomes [43]. Scientific literature about patient
preferences in head and neck oncology is scarce outside of larynx
preservation [44] but when asked about their preferences, head
and neck cancer patients ultimately prioritize survival over quality
of life [45]. It might be hypothesized, although this remains to be
proven, that the reduction of subacute and chronic side effects
observed after IMPT could reduce some of the costs associated with
the delivery of this advanced technique [39].
Designing a comparative study of IMPT versus IMRT for head
and neck cancer is challenging. It is widely accepted that patient-
reported outcomes should be the measure of interest [46,47], but
no set of such outcomes is currently accepted as standard by the
medical community for head and neck cancer patients, although
several tools have been developed for this purpose. Also, clinically
meaningful differences in patient-reported outcomes for remains
to be evaluated. As no literature is available on such outcomes
for head and neck patients treated with proton therapy, no statis-
tical hypothesis or sample size calculation is feasible. In this
context, our study suggests that the chronic presence of a feeding
tube or a significant weight loss from baseline is a reasonable
composite study endpoint that could be meaningful both for
patients and physicians. The systematic collection of patient-
reported outcomes and objective radiographic swallowing data
(via modified barium swallow studies) at baseline, during treat-
ment, and at follow-up as secondary endpoints would then provide
the basis for evaluating patient-reported differences between these
two treatments and the basis for evaluating the value of IMPT.
In conclusion, this case-matched analysis of patients with OPC
treated with either IMPT or IMRT suggests, although additional
54 Proton versus photon therapy for oropharynx cancerfollow-up and patients are needed, that IMPT provides similar
tumor control and lower rates of subacute and late swallowing-
related morbidity than IMRT, as measured by the rate of feeding
tube dependency and/or severe weight loss. Given their potential
consequences in terms of treatment selection, it is essential that
our findings be replicated through prospective multicenter trials,
ideally prospective such as the ongoing phase 2–3 randomized trial
NCT01893307, or by using a model based approach, as advocated
in Europe, and incorporate cost-effectiveness analysis as well as
patient-reported outcomes.Grant or financial support
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